search-icon
AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wing Cloud shuts down after raising $20 million to reinvent cloud development
2
Palo Alto Networks founder Nir Zuk: “We can’t keep relying on cyber as the engine of Israeli high-tech”
3
Deel ‘spy’ avoids punishment as Irish court targets company’s CEO and legal team
4
Groundcover raises $35M Series B to dethrone Datadog with a new observability model
5
SentinelOne caught in Trump’s crosshairs over ex-cyber chief Krebs
More news Buzzmore

Gilead

6 stories about Gilead
מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
ההכרזה של דולנד טראמפ על ירושלים 2

CTech’s Daily Israeli Tech News Roundup

10.12.17|CTech
Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.
default image

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
default image

Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients

30.08.17|Dror Reich
With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
default image

Gilead To Buy Kite Pharma for $11.9 Billion

29.08.17|Dror Reich
The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales
ProfilesEngineServlet?at=39&mi=10&pt=18&dpi=1243103233&pai=cTech&dpn=4409&mt=1